Search results

Page results

• Single-dose radiotherapy as effective for treating breast cancer, long-term study finds

  A pioneering breast cancer therapy developed by UCLH and UCL, which requires just one shot of radiotherapy rather than conventional weeks-long treatment, has proven to be as effective for most women in treating the disease.

• Age no criterion for decisions on heart attack treatment, new research finds

  Elderly patients suffering the most common type of heart attack may benefit from more invasive treatment, new research involving UCLH has shown.

• Loss of smell a ‘highly specific’ indicator of Covid-19, finds UCLH and UCL research

  Acute loss of sense of smell should be considered globally as a criterion for self-isolation, testing, and contact tracing for Covid-19 infection according to researchers at UCLH and UCL.

• King’s Coronation Medal awarded to our head of operations

  Alison Clements, head of operations, patient flow and EPRR, has received a medal in recognition of her work to support NHS preparations for the Coronation of Charles III and Camilla last May.

• Dangoor Family’s Exilarch’s Foundation gift to speed up pioneering cancer care at UCLH

  UCLH Charity is delighted to announce that the Dangoor Family’s Exilarch’s Foundation has pledged a £1.2m gift to support the next phase of the development of the CAR T programme at University College London Hospitals NHS Foundation Trust (UCLH). The CAR T Speed Release Project aims to reduce the time between extracting patient’s stem cells and injecting re-engineered CAR T cells back into patients with cancer to fight cancer cells.

• New national study on long-term health impacts of COVID-19 launched

  UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.

• Increase in delirium, rare brain inflammation and stroke linked to COVID-19

  Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.

• Cystic fibrosis drug tested to fight inflammation in COVID-19

  Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.

• Red Cell Patient Information

  Patient information for Red Cell Network patients

• Patient education and training videos

  Education and training videos for Red Cell Network patients